Curanex Pharmaceuticals Inc (CURX)
8.60
+0.41 (4.95%)
Inactive · Last trade price
on Sep 12, 2025
Company Description
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases.
It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout.
The company was formerly known as Fordman Pharma Inc. and changed its name to Curanex Pharmaceuticals Inc in November 2023.
The company was founded in 1996 and is headquartered in Jericho, New York.
Curanex Pharmaceuticals Inc
| Country | United States |
| Founded | 2018 |
| IPO Date | Aug 26, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Jun Liu |
Contact Details
Address: 2 Jericho Plaza, Suite 101B Jericho, New York 11753 United States | |
| Phone | 718 673 6078 |
| Website | curanexpharma.com |
Stock Details
| Ticker Symbol | CURX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0002025942 |
| ISIN Number | US23126K1060 |
| Employer ID | 83-0741390 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jun Liu | Chief Executive Officer, President and Director |
| Dian Ying Jing | Director and Secretary |
| Haiyan Yang | Chief Financial Officer and Treasurer |
| Huijuan Zhong | Chief Science Officer |
| Liqin Xie | Chief Operating Officer |
| Ning Zhang | Chief Technology Officer |
| Yong Yan | Independent Director |
| Yanming Du | Independent Director |
| Xiaohui Hao | Independent Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 12, 2025 | 8-K | Current Report |
| Sep 9, 2025 | 10-Q | Quarterly Report |
| Aug 27, 2025 | 8-K | Current Report |
| Aug 26, 2025 | 424B4 | Prospectus |
| Aug 26, 2025 | 424B4 | Prospectus |
| Aug 26, 2025 | 8-K | Current Report |
| Aug 25, 2025 | CERT | Certification by an exchange approving securities for listing |
| Aug 25, 2025 | 8-A12B | Registration of securities |
| Aug 12, 2025 | EFFECT | Notice of Effectiveness |
| Jul 22, 2025 | FWP | Free Writing Prospectus |